SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) presented preclinical
data for its recently announced investigational compound, APD418, a
first-in-class calcium-independent myofilament derepressor (CMD),
ß3 adrenergic receptor (AdrR) selective antagonist, at
the American Heart Association Scientific Sessions 2018.
APD418 is being developed to improve cardiac contractility with
minimal effect on heart rate and blood pressure for decompensated
heart failure (DHF).
"A significant unmet medical need exists in the treatment of
decompensated heart failure, the most common hospital diagnosis for
patients over the age of 65, which continues to increase with the
aging population," said Preston
Klassen, MD, MHS, Executive Vice President, Research and
Development and Chief Medical Officer of Arena. "We are
pleased to present new preclinical data demonstrating the potential
of our first-in-class compound, APD418, to improve therapeutic
options by enhancing cardiac contractility while avoiding the
serious adverse events commonly associated with the current
standard of care."
Presentation Details
Session Title: New
Insights into Pharmacological Therapy of CHF
Title: APD418, A Selective Beta3-Adrenergic Receptor
Antagonist Enhances Cardiac Positive Inotropic and Lusitropic
Responses to Dobutamine in Conscious, Chronically-Instrumented Dogs
with Pacing-Induced Heart Failure: Assessment by Pressure-Volume
Analysis (Rapid Fire Oral)
Session Title: Kenneth D.
Bloch Memorial Lecture
Title: Adverse
Functional Significance of Cardiac Beta3-Adrenergic Receptor
Activation on Left Ventricular Contractile Performance in
Conscious, Chronically-Instrumented Dogs with Pacing-Induced Heart
Failure (Oral)
About APD418
APD418 is a first-in-class
calcium-independent myofilament derepressor (CMD) for decompensated
heart failure (DHF). APD418 is a ß3 adrenergic receptor
(AdrR) selective antagonist designed to improve cardiac
contractility with minimal effect on heart rate and blood pressure.
Inhibition of ß3 AdrR mediated myofilament repression may provide a
unique cardiomyocyte-specific target to enhance cardiac contractile
performance while avoiding adverse events associated with current
inotrope therapies. Arena discovered and developed this
investigational drug candidate internally.
APD418 is preclinical, investigational compound that is not
approved for any use in any country.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility. Ralinepag
(APD811) is being evaluated in a Phase 3 program for pulmonary
arterial hypertension (PAH). Etrasimod (APD334), with
potential utility in a broad range of immune and inflammatory
conditions, is being evaluated with late-stage clinical programs in
ulcerative colitis (UC) and Crohn's disease, as well as progressing
programs for primary biliary cholangitis and atopic dermatitis.
Arena is also evaluating olorinab (APD371) with a Phase 2 program
for gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
In addition, Arena has several collaborations including with
Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer
Ingelheim International GmbH (undisclosed target - preclinical),
Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai
Co., Ltd. and Eisai Inc. (BELVIQ® - marketed
product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "in development for," "being developed
to," "potential," "designed to," "may," "driven to," "potentially,"
"potentially," or words of similar meaning, or they may be
identified by the fact that they do not relate strictly to
historical or current facts. Such forward-looking statements
include, without limitation, statements about the following: the
opportunity, development and potential of APD418 and Arena's other
investigational drug candidates, including to be first- or
best-in-class or transformative, improve therapeutic options and
avoid serious adverse events; Arena's drive; and the potential of
Arena's assets, programs, and collaborations. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include:
the timing and outcome of research, development and regulatory
review is uncertain; results of clinical trials and other studies
are subject to different interpretations and may not be predictive
of future results; nonclinical and clinical data are voluminous and
detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Arena or others, request additional information, have additional
recommendations or change their guidance or requirements before or
after approval; we expect to need additional funds to advance all
of our programs, and you and others may not agree with the manner
we allocate our resources; clinical trials and other studies may
not proceed at the time or in the manner expected or at all;
enrolling patients in our ongoing and intended clinical trials is
competitive and challenging; our drug candidates may not advance in
development or be approved for marketing; unexpected or unfavorable
new data; risks related to developing and commercializing drugs;
risks related to relying on partners and other third parties;
Arena's and third parties' intellectual property rights; and
satisfactory resolution of litigation or other disagreements with
others. Additional factors that could cause actual results to
differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with
the Securities and Exchange Commission (SEC), including but not
limited to our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018, which was
filed with the SEC on November 8,
2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-preclinical-data-for-apd418-in-development-for-treatment-of-decompensated-heart-failure-at-american-heart-association-scientific-sessions-300748702.html
SOURCE Arena Pharmaceuticals, Inc.